nafamostat has been researched along with Diabetes Mellitus, Type 2 in 3 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| La Bonte, LR | 2 |
| Dokken, B | 1 |
| Davis-Gorman, G | 2 |
| Stahl, GL | 2 |
| McDonagh, PF | 2 |
| Kawashima, S | 1 |
| Kaneto, H | 1 |
| Sakamoto, K | 1 |
| Honsho, I | 1 |
| Yasuda, T | 1 |
| Kuroda, A | 1 |
| Shiraiwa, T | 1 |
| Kasami, R | 1 |
| Matsuoka, TA | 1 |
| Yamasaki, Y | 1 |
| Matsuhisa, M | 1 |
3 other studies available for nafamostat and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.
Topics: Animals; Antibodies, Monoclonal; Benzamidines; Complement C3; Complement Inactivating Agents; Diabet | 2009 |
Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion.
Topics: Animals; Benzamidines; Blood Cell Count; Blood Glucose; Blood Pressure; CD11b Antigen; Cell Adhesion | 2008 |
Dramatic improvement of subcutaneous insulin resistance with nafamostat ointment treatment.
Topics: Benzamidines; Diabetes Mellitus, Type 2; Female; Guanidines; Humans; Hypoglycemic Agents; Injections | 2008 |